ERBB2 and neoplasm: A possible read-out parameter for treatment effectiveness in HER2+ BC in future HTM studies could be the degree of soluble HER2 ECD in the serum, which was reduced in trastuzumab-treated HTM and which correlated with a reduced tumor volume.